Emilie Aschenbrenner, PharmD, BCOP, paints a vivid picture of how Froedtert Health and the Medical College of Wisconsin are spearheading a paradigm shift in cancer care delivery. Through innovative outpatient-based models, standardized protocols, and strategic partnerships, they are not only enhancing the cost-effectiveness and accessibility of revolutionary therapies like CAR T-cell and bispecific antibody treatments but also revolutionizing the patient experience.
In a recent Institute for Value-Based Medicine® event, Emilie Aschenbrenner, PharmD, BCOP, illuminated the groundbreaking approach adopted by Froedtert Health and the Medical College of Wisconsin to optimize the cost-effectiveness of cutting-edge cancer therapies. By harnessing their 340B status and establishing a robust infrastructure, the institution has seamlessly integrated lymphodepletion chemotherapy and CAR T-cell infusions into outpatient settings. With standardized follow-up procedures and conveniently located patient housing within a 45-minute radius, they have effectively minimized the need for prolonged inpatient stays. This approach is mirrored in the administration of bispecific T-cell engagers, such as teclistamab and talquetamab, with compressed dosing schedules and meticulous follow-up mechanisms designed to reduce hospital admissions and elevate patient satisfaction.
While discussing the introduction of trispecific antibodies, Aschenbrenner highlighted initial concerns surrounding heightened immunogenicity and toxicity. However, emerging trial data indicates that these challenges can be managed effectively, paving the way for the alignment of care pathways for trispecifics with those established for bispecific therapies. By exercising caution and prioritizing provider reeducation, the institution aims to navigate the complexities of these advanced treatments seamlessly, potentially unlocking pathways to earlier lines of therapy and enhanced patient outcomes.
The critical question arises: How can disparities in access to advanced therapies be mitigated for patients in underserved regions and community settings? Aschenbrenner underscores the significance of standardized processes, collaborative partnerships, and shared care models in addressing this issue. Through strategic collaborations, such as the one with ThedaCare, Froedtert Health endeavors to extend the reach of advanced therapies and consistent treatment protocols to a broader, more diverse patient population. By streamlining processes and fostering synergy between institutions, the barriers to accessing innovative treatments can be dismantled, ensuring equitable care delivery for all patients, irrespective of their geographical location or demographic background.
Key Takeaways:
– The integration of outpatient-based care models and standardized protocols can significantly enhance the cost-effectiveness and accessibility of advanced cancer therapies.
– Strategic partnerships and collaborative initiatives play a pivotal role in bridging the gap in access to innovative treatments for underserved populations.
– Careful consideration of toxicity management and provider reeducation is crucial in navigating the complexities of emerging trispecific antibodies and other novel therapies.
– Revolutionizing cancer care delivery through outpatient models not only optimizes cost-effectiveness but also prioritizes patient satisfaction and experience.